Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis

[1]  A. Reiner,et al.  Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor. , 2003, The Journal of rheumatology.

[2]  A. Parker,et al.  Metalloproteinases: their role in arthritis and potential as therapeutic targets , 2003, Expert opinion on therapeutic targets.

[3]  Shigeyoshi Itohara,et al.  The Role of Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 in Antibody-Induced Arthritis , 2002, The Journal of Immunology.

[4]  M. Otagiri,et al.  Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. , 2002, Biological & pharmaceutical bulletin.

[5]  A. Freemont,et al.  Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. , 2001, Osteoarthritis and cartilage.

[6]  F. Spinale,et al.  Matrix Metalloproteinase Inhibition Attenuates Left Ventricular Remodeling and Dysfunction in a Rat Model of Progressive Heart Failure , 2001, Circulation.

[7]  A. Jeng,et al.  The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. , 2001, Current medicinal chemistry.

[8]  M. Natchus,et al.  Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. , 1999, Journal of medicinal chemistry.

[9]  S. Pikul,et al.  Permeability of Articular Cartilage to Matrix Metalloprotease Inhibitors , 1998, Pharmaceutical Research.

[10]  E. J. Lewis,et al.  Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. , 1998, Arthritis and rheumatism.

[11]  P. Gillet,et al.  Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. , 1997, Arthritis and rheumatism.

[12]  J. Pelletier,et al.  Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ: in vitro mimicking effect by transforming growth factor beta. , 1997, Arthritis and rheumatism.

[13]  J. Laydon,et al.  Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNFα processing , 1997, Inflammation Research.

[14]  J. Bishop,et al.  Ro 32‐3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo , 1997, British journal of pharmacology.

[15]  D. Wernicke,et al.  Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis. , 1996, The Journal of rheumatology.

[16]  K. Geoghegan,et al.  Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. , 1996, The Journal of clinical investigation.

[17]  R. Clark,et al.  Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor , 1995, The Journal of experimental medicine.

[18]  L. Lohmander,et al.  Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. , 1993, Arthritis and rheumatism.

[19]  G Murphy,et al.  A novel coumarin‐labelled peptide for sensitive continuous assays of the matrix metalloproteinases , 1992, FEBS letters.

[20]  A. Ladd,et al.  In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. , 1991, Arthritis and rheumatism.

[21]  S S McCachren,et al.  Expression of metalloproteinases and metalloproteinase inhibitor in human arthritic synovium. , 1991, Arthritis and rheumatism.

[22]  P. Anract,et al.  Effect of inhibition of matrix metalloproteinases on cartilage loss in vitro and in a guinea pig model of osteoarthritis. , 2005, Arthritis and rheumatism.

[23]  A. Poole,et al.  Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. , 2001, The Journal of clinical investigation.

[24]  J. Mudgett,et al.  Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. , 1998, Arthritis and rheumatism.

[25]  N. Bhardwaj,et al.  Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. , 1992, Arthritis and rheumatism.